Dhwani Patel
Overview
Explore the profile of Dhwani Patel including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
30
Citations
360
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Tan C, Wang A, Nemirovsky D, Derkach A, Shekarkhand T, Hamadeh I, et al.
Blood Adv
. 2025 Mar;
PMID: 40048741
No abstract available.
2.
Akhlaghi T, Maclachlan K, Korde N, Mailankody S, Lesokhin A, Hassoun H, et al.
Haematologica
. 2024 Oct;
110(2):493-497.
PMID: 39363855
No abstract available.
3.
Hultcrantz M, Hassoun H, Korde N, Maclachlan K, Mailankody S, Patel D, et al.
Blood Cancer J
. 2024 Sep;
14(1):164.
PMID: 39300066
No abstract available.
4.
Hultcrantz M, Hassoun H, Korde N, Maclachlan K, Mailankody S, Patel D, et al.
Res Sq
. 2024 Jun;
PMID: 38883739
Lenalidomide maintenance is associated with a significantly improved progression-free in patients with newly diagnosed multiple myeloma. Maintenance with lenalidomide is generally well tolerated; however, lenalidomide associated diarrhea is a common...
5.
Hamadeh I, Shekarkhand T, Rueda C, Firestone R, Wang A, Korde N, et al.
Blood Adv
. 2024 Apr;
8(12):3038-3044.
PMID: 38598713
Teclistamab (Tec) is a first-in-class BCMA × CD3 bispecific T-cell engager antibody approved for treating multiple myeloma progressing after at least 4 lines of therapy. The objective of this study...
6.
Hunsaker J, Laulu S, Zupan E, Patel D, Pandya V, Rudolf J
Ann Lab Med
. 2024 Mar;
44(4):367-370.
PMID: 38481373
No abstract available.
7.
Firestone R, McAvoy D, Shekarkhand T, Serrano E, Hamadeh I, Wang A, et al.
Blood Adv
. 2023 Oct;
8(7):1600-1611.
PMID: 37878808
Teclistamab, a B-cell maturation antigen (BCMA)- and CD3-targeting bispecific antibody, is an effective novel treatment for relapsed/refractory multiple myeloma (R/RMM), but efficacy in patients exposed to BCMA-directed therapies and mechanisms...
8.
Patel D, Murray I, Dong F, Annalora A, Gowda K, Coslo D, et al.
Metabolites
. 2023 Sep;
13(9).
PMID: 37755265
The aryl hydrocarbon receptor (AHR) is a ligand-activated transcription factor that plays an important role in gastrointestinal barrier function, tumorigenesis, and is an emerging drug target. The resident microbiota is...
9.
Tan C, Derkach A, Nemirovsky D, Ciardiello A, Diamond B, Hultcrantz M, et al.
Blood Cancer J
. 2023 Jul;
13(1):112.
PMID: 37491332
Lenalidomide and dexamethasone with bortezomib (VRd) or carfilzomib (KRd) are commonly used induction regimens in the U.S. This single-center, retrospective study evaluated outcomes and safety of VRd and KRd. Primary...
10.
Tan C, Derkach A, Nemirovsky D, Ciardiello A, Diamond B, Hultcrantz M, et al.
Res Sq
. 2023 Mar;
PMID: 36865246
Lenalidomide and dexamethasone with bortezomib (VRd) or carfilzomib (KRd) are commonly used induction regimens in the U.S. This single-center, retrospective study evaluated outcomes and safety of VRd and KRd. Primary...